DCM
FATE icon

Delpha Capital Management’s Fate Therapeutics FATE Stock Holding History

Delpha Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-993
Closed -$6K – 476
2017
Q4 		$6K Buy
+993
New +$4.43K 0.01% 1215

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Delpha Capital Management's FATE Position: Q1 2018 in Review

Delpha Capital Management sold out of Fate Therapeutics (FATE) in Q1 2018, closing a stake of 993 shares — an estimated $6K sold.

Delpha Capital Management first reported a position in FATE in Q4 2017 and held it in 1 quarter. The position peaked at $6K in Q4 2017. 90 funds tracked by Wall St. Rank hold FATE as of Q1 2018.

  • Delpha Capital Management reported no remaining Fate Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 993 Fate Therapeutics shares in Q1 2018, an estimated $6K.
  • Delpha Capital Management first reported a position in Fate Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Fate Therapeutics position peaked at $6K in Q4 2017.
  • 90 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.